Abstract: The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for use in the treatment or prophylaxis of condition mediated by an androgen receptor.
Type:
Application
Filed:
March 4, 2005
Publication date:
January 31, 2008
Inventors:
Neeraj Garg, Eva Kristina Kock, Henrik Per Hakan Jernstedt, Mikael Johan Gillner
Abstract: Pharmaceutical delivery systems suitable for topical administration including benzoyl peroxide. In a particular aspect, these pharmaceutical delivery systems comprise at least one pad and a drug composition comprising benzoyl peroxide absorbed onto the pad. These compositions are used for topical medical applications, particularly to treat various skin disorders.
Abstract: A method for the treatment of skin damage using strontium divalent ion in a dermatologically acceptable carrier is provided, usually an essential oil distillate. The compositions are applied topically to improve appearance of skin damaged by sun or by natural aging. The compositions may additionally include antioxidant molecules such as vitamin E, ferulic acid and vitamin C.
Abstract: A method of treating skin changes and conditions in human skin including applying a topical preparation that includes an active agent including probucol, a derivative of probucol or a combination of probucol and a derivative of probucol.
Abstract: Disclosed and described herein are compounds of the formula or a pharmaceutically acceptable salt thereof, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed and described.
Abstract: A composition which causes adult boring bark beetles to discontinue boring, discontinue laying eggs and become disoriented and bore out of the tree or cease boring altogether and die is described. Additional tests have shown that beetles will not infest a tree which has been treated with the composition. Furthermore, the composition also causes beetle larvae to cease boring and die and also causes egg sacks to shrivel and die.
Abstract: A compound or a salt thereof having the atom corresponding to N3 and the two or more atoms selected from N1, N2, N4 and N5, said atoms constitute the pharmacophore represented by the following formula: and inhibits the activity of transcription factor AP-1 and is useful as an agent for preventing and treating the diseases into which over expression of AP-1 participates and as an AP-1 inhibitor.
Abstract: A compound of formula (I) wherein T represents O, S or NR and wherein R represents a H, a C1-6alkyl group or a phenyl C1-6alkyl group and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and and pharmaceutical compositions containing them
Abstract: The present invention relates to a process for the preparation of cis substituted cyclic ?-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined herein and corresponding salts thereof.
Type:
Application
Filed:
March 30, 2007
Publication date:
October 4, 2007
Inventors:
Stephan Bachmann, Michelangelo Scalone, Patrick Schnider
Abstract: A system is disclosed consisting of tea tree oil used alone or in combination with conventional over-the-counter strength anti-acne agents. A system is created whereby Tea tree oil is used in combination with other anti-acne therapies, particularly benzoyl peroxide. Subsequent steps utilize conventional anti-acne treatments.
Abstract: The present invention provides new amyloidogenesis inhibiting compounds of formula (I): in which R1 is a —NRaRb group, where Ra and Rb, independently, are a hydrogen atom or a C1-C6 alkyl group; —ORC group, where RC is a hydrogen atom or a C1-C6 alkyl group; a glycosyl; a C1-C6 polyhydroxyalkyl; or a —NH—CH(Rd)—COORe group, where Rd is a side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and Re is a hydrogen atom or a C1-C6 alkyl group; and R2 is a hydrogen atom, a C1-C6 alkyl group, a glycosyl; a C1-C6 polyhydroxyalkyl; —C(?O)—Rf group, where Rf is a C1-C6 alkyl group; or a —CH2—COO—Rg group, where Rg is a hydrogen atom or a C1-C6 alkyl group; and pharmaceutically acceptable salts thereof, which are useful in the treatment of neurodegenerative diseases, among others.
Type:
Grant
Filed:
October 8, 2003
Date of Patent:
September 4, 2007
Assignee:
Innovaprotean, S.L
Inventors:
Maria Joao Mascarenhas Saraiva, Maria do Rosario Rodrigues Almeida, José Barluenga Mur, Alfredo Ballesteros Gimeno, Antoni Planas Sauter, Gemma Arsequell Ruiz, Gregorio Valencia Parera
Abstract: This invention relates to formulations containing a combination of anisic acid, or a salt thereof, or an ester thereof, and a C6-14 fatty acid monoglyceride and to the use of such combinations as a preservative system.
Type:
Grant
Filed:
December 13, 2004
Date of Patent:
August 28, 2007
Assignee:
Johnson & Johnson Consumer France SAS
Inventors:
Florence Baranger, Jean Francois Porracchia
Abstract: The present invention relates to compositions comprising telmesteine, glycyrrhetinic acid, and a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compositions comprising a proanthocyanidin, glycyrrhetinic acid and telmesteine, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye.
Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2, Rx, R8, R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
Type:
Grant
Filed:
April 7, 2003
Date of Patent:
June 19, 2007
Assignee:
Glaxo Group Limited
Inventors:
Gerard Martin Paul Giblin, Adrian Hall, David Nigel Hurst, Ian Reginald Kilford, Xiao Qing Lewell, Alan Naylor, Riccardo Novelli
Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.
Type:
Grant
Filed:
September 29, 2005
Date of Patent:
May 8, 2007
Assignee:
Warner-Lambert Company
Inventors:
Nicole Chantel Barvian, David Thomas Connor, Richard Dennis Dyer, Adam Richard Johnson, William Chester Patt
Abstract: The present invention provides ethyl (?)-2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxy]acetate hydrochloride, crystalline forms thereof and pharmaceutical compositions containing them, which have excellent ?3-adrenoceptor stimulating effects, therapeutic effects on pollakiuria or urinary incontinence and storage stabilities and are useful as a medicament.
Abstract: The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof, useful for delivering agents having the capacity to diagnose, treat or prevent bone injury or disease to the bone for interaction therewith.
Type:
Grant
Filed:
December 22, 2004
Date of Patent:
March 27, 2007
Assignee:
University of Louisville Research Foundation, Inc.
Inventors:
William M. Pierce, Jr., Leonard C. Waite, K. Grant Taylor
Abstract: Germicidal compositions with enhanced activity towards killing microbiological spores and vetgetative cells comprising certain quaternary ammonium compounds (QACs), phenolic compounds, monohydric alcohols, hydrogen peroxide, iodine, triclocarban, triclosan or combinations thereof with one or more spore coat opening agents. The invention also provides for the application of the germicidal compositions to animate and inanimate surfaces to help kill germs and protect against the risk of infection from bacteria, molds, yeasts, fungi, viruses, and microbiological spores.
Abstract: The present invention releates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Abstract: The present application is directed to the use of X-ray contrast media that act as universal antigens that are labeled herein as “pseudoantigens.” X-ray contrast media have the potential to exist in an aggregated state that is greater in increased concentrations. In this aggregated state, contrast media assume the role of multivalent antigens and can successfully compete with any other antigens involved in antibody-antigen reactions that lead to anaphylaxis. In this competition, the large quantity of contrast media serves to inhibit the adverse effects of antibody-antigen reactions without the contrast media itself creating antibodies or creating toxicity problems.
Abstract: The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
November 21, 2006
Assignee:
Warner Lambert Company
Inventors:
David James Dooley, David Juergen Wustrow
Abstract: The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.
Abstract: The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.
Type:
Grant
Filed:
February 25, 2003
Date of Patent:
October 17, 2006
Assignee:
The Regents of the University of California
Inventors:
Daniel M. Schwartz, John D. Baxter, Michele D. Jumper, Thomas S. Scanlan
Abstract: This invention relates to a method for the treatment of acne that comprises applying a fluid comprising a polyalkylene carbonate over the area affected by acne and penetrating pores within the area. Forming a polyalkylene carbonate film covering the affected area, and thereafter removing the film. The polyalkylene carbonate film can also contain medications useful in the treatment of acne.
Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.
Abstract: The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, pharmaceutical compositions containing them, and methods for using them for treatment of cardiovascular disorders are also disclosed and claimed.
Type:
Grant
Filed:
August 31, 2000
Date of Patent:
August 8, 2006
Assignee:
Bayer Aktiengesellschaft
Inventors:
Cristina Alonso-Alija, Markus Heil, Dietmar Flubacher, Paul Naab, Josef Pernerstorfer, Johannes-Peter Stasch, Frank Wunder, Klaus Dembowsky, Elisabeth Perzborn, Elke Stahl
Abstract: The present invention relates to an inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, specific hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof. The inhibitors according to the present invention are useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases. In addition, the present invention also provides novel hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof.
Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases
Type:
Grant
Filed:
June 24, 2002
Date of Patent:
June 20, 2006
Assignee:
Bayer Healthcare AG
Inventors:
Thomas Rolle, Thomas Lehmann, Markus Albers, Gerhard Muller, Gerhard Hessler, Rudiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
Abstract: The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.
Type:
Grant
Filed:
June 26, 2003
Date of Patent:
June 13, 2006
Inventors:
Cathy Klech Gelotte, Joanna F. Hills, Charles E. Pendley, II, Manoj N. Shah
Abstract: Disclosed are insect baits for attracting insects such as ants, flies and cockroaches. The baits include amino acids and a sugar. The baits can be combined with an insect toxicant to effectively control and eliminate insect populations. Methods for controlling insects using an insect bait of the invention are also disclosed.
Type:
Grant
Filed:
August 6, 2003
Date of Patent:
May 23, 2006
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Jack Richard Warner, Rudolf H. Scheffrahn
Abstract: The inventions relates to the use of silica in the formulation of antifungal composition for the treatment of cutaneous mycoses, and method to manufacture an antifungal powder with boric acid and silica.
Abstract: The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become disturbed by these modifications and can result in severe consequences. The compounds of the present invention can be used to inhibit this process of nonenzymatic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compounds are also useful for preventing premature aging, spoilage of proteins in food and can prevent discoloration of teeth.
Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.
Type:
Grant
Filed:
September 26, 2002
Date of Patent:
April 18, 2006
Assignee:
POZEN Inc.
Inventors:
John R. Plachetka, Zakauddin T. Chowhan
Abstract: The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Grant
Filed:
January 29, 2003
Date of Patent:
April 11, 2006
Assignee:
Warner-Lambert Company
Inventors:
David James Dooley, David Juergen Wustrow
Abstract: The present invention is a compound represented by the following formula (1) or (2): where one of R1 and R2 is hydrogen and the other one is hydrogen or glucose residue. The compound is effective for reforming obese constitution, suppressing or preventing obesity. It is also effective for skin whitening.
Abstract: The invention relates to disinfecting agents for combating and inactivating phytopathogenic organisms for use on plants and in their environment. The agents are based on a mixture of anionic, active surfactants, aliphatic and aromatic carboxylic acids, glycols, hydrotropic agents and aliphatic, monovalent alcohol, and are characterized in that they contain, together with hydrotropic agents and monovalent alcohols, a combination of aliphatic and aromatic carboxylic acids determined from alkyl- and/or alkylarylsulfonates as well as contain glycols determined individually or in a mixture as solvent.
Type:
Grant
Filed:
September 25, 1999
Date of Patent:
February 28, 2006
Assignee:
Menno Chemie Vertriebsges, mbH
Inventors:
Jan Nevermann, Wolfgang Zerling, Jutta Hoffler
Abstract: This invention provides a method of improving the sweetness delivery profile of a sucralose-containing ingestible composition, which comprises incorporating therein DHB at a DHB:sucralose weight ratio of from about 0.01% to about 100%.
Abstract: A readily water-soluble ingestible form of ketoprofen is provided by the reaction of ketoprofen and any edible weak base to yield a palatable, stable, safe pharmaceutical solution for mass medication of animals. Any edible weak base such as sodium bicarbonate may be used with ketoprofen in a ratio of 10 to 1 by weight.
Abstract: A stable pharmaceutical composition comprising a mixture of (i) an ibuprofen medicament; (ii) a domperidone medicament and (iii) a carrier material characterized in that the carrier material is substantially free of providone and comprises at least one diluent combined with at least one release modifying agent.
Abstract: Methods of inhibiting lipofibroblast to myofibroblast transdifferentiation in a mammal are disclosed comprising administering a PPAR gamma ligand when said mammal is exposed to a hyperoxic condition.
Type:
Grant
Filed:
January 27, 2003
Date of Patent:
January 31, 2006
Assignee:
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
Abstract: Compounds that are dual aP2/k-FABP inhibitors are provided having the formula wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
Type:
Grant
Filed:
November 15, 2002
Date of Patent:
January 10, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
David R. Magnin, Richard B. Sulsky, Jeffrey A. Robl, Thomas J. Caulfield, Rex A. Parker
Abstract: This invention relates to biocidal compositions and methods of using same. Also provided is a process for the manufacturing of a biocidal composition in the form of a tablet and a method of using the biocidal compositions for the disinfection of water that may contain microorganisms and biofilms.
Type:
Grant
Filed:
July 15, 2003
Date of Patent:
January 3, 2006
Assignee:
Sani-Care Salon Products, Inc.
Inventors:
Su Mingzhong, Long Truong Hoang, Linh Truong Hoang
Abstract: Methods for the treatment of diseases or pathological states related to the degradation of the extracellular matrix, such as degenerative diseases atheriosclerosis, cancer, infection or other inflammatory diseases are disclosed, comprising administering compositions of lysine, proline, ascorbate, and their derivatives and synthetic analogues and vitamins, pro-vitamins and trace elements.
Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
Type:
Grant
Filed:
November 2, 2004
Date of Patent:
November 15, 2005
Assignee:
Warner-Lambert Company, LLC
Inventors:
Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
Abstract: Cosmetic or dermatological composition characterized in that it comprises a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent.
Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
Type:
Grant
Filed:
November 28, 2005
Date of Patent:
November 6, 2007
Assignee:
Warner Lambert Company
Inventors:
Bruce J. Auerbach, Larry D. Bratton, Gary Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst